Your browser doesn't support javascript.
loading
Poly(ADP-Ribose) Polymerase Inhibitor Development: Promising Strategies to Move Beyond Approved Indications.
Torrado, Carlos; Plummer, Ruth; Yap, Timothy A.
Affiliation
  • Torrado C; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Plummer R; Newcastle University and Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust, Newcastle Upon Tyne, United Kigdom.
  • Yap TA; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX.
JCO Precis Oncol ; 8: e2400204, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38865670
ABSTRACT
Biomarker-based patient selection and rational combinations show promise in expanding the use of PARP inhibitors.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Poly(ADP-ribose) Polymerase Inhibitors Limits: Humans Language: En Journal: JCO Precis Oncol Year: 2024 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Poly(ADP-ribose) Polymerase Inhibitors Limits: Humans Language: En Journal: JCO Precis Oncol Year: 2024 Document type: Article